SCHEMBL26197747

SCHEMBL26197747

Fc1c(Cl)ncc2c(N3CC4CCC(C4)C3)nc(OCC34CCCN3C[C@H](F)C4)nc12

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26196915 1.00 KRAS (0.63) KRAS
SCHEMBL25079374 1.00 KRAS (0.63) KRAS
SCHEMBL30922496 0.92 KRAS (0.63) KRAS
SCHEMBL26196655 0.91 KRAS (0.60) KRAS
SCHEMBL31551900 0.91 KRAS (0.60) KRAS
SCHEMBL27117497 0.91 KRAS (0.61) KRAS
SCHEMBL25403042 0.91 KRAS (0.61) KRAS
SCHEMBL25079055 0.91 KRAS (0.61) KRAS
SCHEMBL23054156 0.90 KRAS (0.77) KRAS
SCHEMBL29931450 0.90 KRAS (0.77) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS KRAS 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback